9:00 -9:10 a.m. 9:10 -9:25 a.m. 9:25 -9:45 a.m. 9:45 -10:05 a.m. 10:05 -10:20 a.m. 10:20 -10:30 a.m. 10:30 -10:45 a.m. 10:45 -11 :00 a.m. FOGHORN' THlaRAPlaVTICS Welcome and Introduction Adrian Gottschalk, P resident and CEO, Foghorn Therapeutics Chromatin Regulatory System -Disease Relevance Cigall Kadoch, Ph.D., Broad Institute, DFCI, Scientific Co-founder Foghorn Therapeutics Gene Traffic Control Platform Steve Bellon, Ph.D, SVP, Head of Drug Discovery, Foghorn Therapeutics FHD-286 -Clinical Applications of Dual BRM/BRG1 Inhibition Sam Agresta, MP, MPH & TM, CMO, Foghorn Therapeutics Acute Myeloid Leukemia Eytan Stein, M.D., Memorial Sloan Kettering Cancer Center Synovial Sarcoma -FHD-609 Sam Agresta, MP, MPH & TM, CMO, Foghorn Therapeutics Targeting the Chromatin Regulatory System in Cancer Howard "Skip" Burris 111, MD, FASCO, FACP, Sara Cannon Research Institute Q&A
9:00 -9:10 a.m. 9:10 -9:25 a.m. 9:25 -9:45 a.m. 9:45 -10:05 a.m. 10:05 -10:20 a.m. 10:20 -10:30 a.m. 10:30 -10:45 a.m. 10:45 -11 :00 a.m. FOGHORN' THlaRAPlaVTICS Welcome and Introduction Adrian Gottschalk, P resident and CEO, Foghorn Therapeutics Chromatin Regulatory System -Disease Relevance Cigall Kadoch, Ph.D., Broad Institute, DFCI, Scientific Co-founder Foghorn Therapeutics Gene Traffic Control Platform Steve Bellon, Ph.D, SVP, Head of Drug Discovery, Foghorn Therapeutics FHD-286 -Clinical Applications of Dual BRM/BRG1 Inhibition Sam Agresta, MP, MPH & TM, CMO, Foghorn Therapeutics Acute Myeloid Leukemia Eytan Stein, M.D., Memorial Sloan Kettering Cancer Center Synovial Sarcoma -FHD-609 Sam Agresta, MP, MPH & TM, CMO, Foghorn Therapeutics Targeting the Chromatin Regulatory System in Cancer Howard "Skip" Burris 111, MD, FASCO, FACP, Sara Cannon Research Institute Q&A
